TAF vs TDF for the Treatment of HBeAg Positive, Chronic Hepatitis B

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B

• IRAS ID

  137792

• Contact name

  Kosh Agarwal

• Contact email

  kosh.agarwal@nhs.net

• Sponsor organisation

  Gilead Sciences Inc

• Eudract number

  2013-000636-10

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  13/LO/1490

• Date of REC Opinion

  10 Dec 2013

• REC opinion

  Further Information Favourable Opinion